Laddar...
Gilteritinib: potent targeting of FLT3 mutations in AML
Since the discovery of FMS-like tyrosine kinase-3 (FLT3)–activating mutations as genetic drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase inhibitors that could effectively target FLT3 and alter the disease trajectory. Giltertinib (formerly known as ASP2215...
Sparad:
| I publikationen: | Blood Adv |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Hematology
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7094008/ https://ncbi.nlm.nih.gov/pubmed/32208491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000174 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|